Year |
Citation |
Score |
2021 |
Sjoberg HT, Philippou Y, Magnussen AL, Tullis IDC, Bridges E, Chatrian A, Lefebvre J, Tam KH, Murphy EA, Rittscher J, Preise D, Agemy L, Yechezkel T, Smart SC, Kinchesh P, et al. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. British Journal of Cancer. PMID 34155340 DOI: 10.1038/s41416-021-01450-6 |
0.444 |
|
2018 |
Goldschmidt R, Koudinova N, Sasson K, Preise D, Agemy L, Mohan V, Bochner F, Sagi I, Neeman M, Scherz A. Vascular targeted photodynamic therapy for pancreatic ductal adenocarcinoma: A pre-clinical success Annals of Oncology. 29: iii21. DOI: 10.1093/Annonc/Mdy047.045 |
0.45 |
|
2017 |
Uzana R, Preise D, Agemy L, Elmualem R, Kelsen D, Gerdes H, Coleman J, Murray K, Belkin V, Sasson K, Yehezkel T, Salomon Y, Scherz A. A novel vascular targeted photodynamic therapy (VTP) in orthotopic rat model for the treatment of esophageal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii13-iii14. PMID 32135740 DOI: 10.1093/Annonc/Mdx261.002 |
0.663 |
|
2016 |
Uzana R, Preise D, Agemy L, Elmoalem R, Belkin V, Sasson K, Yechezkel T, Salomon Y, Scherz AJ. Palliative treatment of obstructive esophageal cancer by vascular targeted photodynamic therapy (VTP): Preclinical study in orthotopic rat model. Journal of Clinical Oncology. 34: 59-59. DOI: 10.1200/Jco.2016.34.4_Suppl.59 |
0.71 |
|
2016 |
Preise D, Kudinova N, Lindner U, Sasson K, Uzana R, Coleman J, Salomon Y, Scherz A. Abstract B012: Immunomodulated VTP enables cure of metastatic prostate and breast cancers in animal models Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B012 |
0.691 |
|
2016 |
Lindner U, Preise D, Kudinova N, Agaronov A, Salomon Y, Coleman J, Leibovichi D. 38 Preventing occurrence of metastatic disease in rats with locally advanced prostate cancer by immunomodulation and vascular targeted therapy European Urology Supplements. 15: e38. DOI: 10.1016/S1569-9056(16)60040-4 |
0.632 |
|
2016 |
Lindner U, Preise D, Kudinova N, Agarounov A, Salomon Y, Coleman JA, Leibovici D, Scherz A. MP62-07 NEOADJUVANT IMMUNOMODULATION COMBINED WITH VASCULAR TARGETED THERAPY PREVENTS METASTASES AND IMPROVES SURVIVAL IN RATS WITH LOCALLY ADVANCED PROSTATE CANCER. Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.915 |
0.644 |
|
2015 |
Uzana R, Preise D, Agemy L, Elmoalem R, Brandis A, Belkin V, Salomon Y, Scherz A. The treatment of esophageal cancer by vascular-targeted photodynamic therapy (VTP) using orthotopic rat model. Journal of Clinical Oncology. 33: 91-91. DOI: 10.1200/Jco.2015.33.3_Suppl.91 |
0.706 |
|
2011 |
Preise D, Scherz A, Salomon Y. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP). Photochemical & Photobiological Sciences : Official Journal of the European Photochemistry Association and the European Society For Photobiology. 10: 681-8. PMID 21258718 DOI: 10.1039/C0Pp00315H |
0.712 |
|
2009 |
Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunology, Immunotherapy : Cii. 58: 71-84. PMID 18488222 DOI: 10.1007/S00262-008-0527-0 |
0.69 |
|
2008 |
Fleshker S, Preise D, Kalchenko V, Scherz A, Salomon Y. Prompt assessment of WST11-VTP outcome using luciferase transfected tumors enables second treatment and increase in overall therapeutic rate. Photochemistry and Photobiology. 84: 1231-7. PMID 18399928 DOI: 10.1111/J.1751-1097.2008.00340.X |
0.64 |
|
2003 |
Preise D, Mazor O, Koudinova N, Liscovitch M, Scherz A, Salomon Y. Bypass of tumor drug resistance by antivascular therapy. Neoplasia (New York, N.Y.). 5: 475-80. PMID 14965440 DOI: 10.1016/S1476-5586(03)80031-3 |
0.66 |
|
Low-probability matches (unlikely to be authored by this person) |
2014 |
Kalchenko V, Kuznetsov Y, Preise D, Meglinski I, Harmelin A. Ear swelling test by using laser speckle imaging with a long exposure time. Journal of Biomedical Optics. 19: 060502. PMID 24967913 DOI: 10.1117/1.Jbo.19.6.060502 |
0.261 |
|
2007 |
Kalchenko V, Preise D, Bayewitch M, Fine I, Burd K, Harmelin A. In vivo dynamic light scattering microscopy of tumour blood vessels. Journal of Microscopy. 228: 118-22. PMID 17970911 DOI: 10.1111/J.1365-2818.2007.01832.X |
0.261 |
|
2021 |
Markovic S, Roussel T, Agemy L, Sasson K, Preise D, Scherz A, Frydman L. Deuterium MRSI characterizations of glucose metabolism in orthotopic pancreatic cancer mouse models. Nmr in Biomedicine. e4569. PMID 34137085 DOI: 10.1002/nbm.4569 |
0.254 |
|
2020 |
Marcovich AL, Brekelmans J, Brandis A, Samish I, Pinkas I, Preise D, Sasson K, Feine I, Goz A, Dickman MM, Nuijts RMMA, Scherz A. Decreased Riboflavin Impregnation Time Does Not Increase the Risk for Endothelial Phototoxicity During Corneal Cross-Linking. Translational Vision Science & Technology. 9: 4. PMID 32821501 DOI: 10.1167/Tvst.9.6.4 |
0.249 |
|
2015 |
Govrin-Yehudain J, Dvir H, Preise D, Govrin-Yehudain O, Govreen-Segal D. Lightweight breast implants: a novel solution for breast augmentation and reconstruction mammaplasty. Aesthetic Surgery Journal / the American Society For Aesthetic Plastic Surgery. 35: 965-71. PMID 26333989 DOI: 10.1093/Asj/Sjv080 |
0.219 |
|
2020 |
Martinho RP, Bao Q, Markovic S, Preise D, Sasson K, Agemi L, Scherz A, Frydman L. Identification of variable stages in murine pancreatic tumors by a multiparametric approach employing hyperpolarized C MRSI, H diffusivity and H T MRI. Nmr in Biomedicine. e4446. PMID 33219722 DOI: 10.1002/nbm.4446 |
0.193 |
|
2021 |
Peters DC, Markovic S, Bao Q, Preise D, Sasson K, Agemy L, Scherz A, Frydman L. Improving deuterium metabolic imaging (DMI) signal-to-noise ratio by spectroscopic multi-echo bSSFP: A pancreatic cancer investigation. Magnetic Resonance in Medicine. PMID 34196041 DOI: 10.1002/mrm.28906 |
0.123 |
|
2020 |
Marcovich AL, Brekelmans J, Brandis A, Samish I, Pinkas I, Preise D, Sasson K, Feine I, Goz A, Dickman MM, Nuijts RMMA, Scherz A. Decreased Riboflavin Impregnation Time Does Not Increase the Risk for Endothelial Phototoxicity During Corneal Cross-Linking Translational Vision Science & Technology. 9: 4. DOI: 10.1167/tvst.9.6.4 |
0.098 |
|
Hide low-probability matches. |